Two ACR 2025 analyses link SGLT2 inhibitors to fewer RA flares and a lower risk for osteoarthritis than GLP-1 receptor ...

"Imugene announces Phase Ib azer-cel efficacy data" was originally created and published by Clinical Trials Arena, a ...

Innovent's Pecondle, a recombinant anti-interleukin-23p19 subunit, receives China NMPA approval to treat moderate-to-severe plaque psoriasis: San Francisco Monday, December 1, 202 ...

Using human iPSC-derived kidney organoids, researchers showed that NPHP1 deficiency triggers abnormal Hippo signaling that ...

A simple blood test analysed by artificial intelligence could revolutionise early detection of primary vitreoretinal lymphoma ...

Imugene Ltd (ASX:IMU, OTC:IUGNF) has reported another uplift in efficacy data from its Phase 1b trial of azer-cel, its allogeneic, off-the-shelf CD19 ...

Sun Pharma introduces Ilumya in India for treatment of moderate-to-severe plaque psoriasis: Our Bureau, Mumbai Tuesday, December 2, 2025, 14:45 Hrs [IST] Sun Pharma has announced ...

Chronic HBV infection remains a major global health burden, with current antiviral therapies effectively suppressing viral ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Recent research published in the Journal of Psychiatric Research indicates that specific clusters of depressive symptoms are ...

Accord BioPharma Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that Express Scripts, one of ...